Sherman Cole, MD
Psychiatry · Leawood, KSNPI 1609856699
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 499 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,410 and has fallen 62.0% since, to $916 in 2025.
Across 499 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$959
- Neurocrine Biosciences, Inc.$540
- Lundbeck LLC$519
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$454
- Takeda Pharmaceuticals U.S.A., Inc.$401
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,948100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,656 |
| Otsuka America Pharmaceutical, Inc. | 48 | $959 |
| Neurocrine Biosciences, Inc. | 30 | $540 |
| Lundbeck LLC | 35 | $519 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $454 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $401 |
| Johnson & Johnson | 19 | $386 |
| Vanda Pharmaceuticals Inc. | 20 | $345 |
| Ironshore Pharmaceuticals Inc. | 10 | $295 |
| Alkermes, Inc. | 11 | $267 |
| Avanir Pharmaceuticals, Inc. | 26 | $249 |
| Neos Therapeutics, LP | 22 | $215 |
| Supernus Pharmaceuticals, Inc. | 9 | $172 |
| Biogen | 7 | $154 |
| Tris Pharma Inc | 8 | $126 |
| MDD US Operations, LLC | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 40 | $123 |
| Shire North American Group Inc | 14 | $111 |
| Teva Pharmaceuticals USA, Inc. | 7 | $110 |
| Corium, LLC | 6 | $106 |
| Bausch Health US, LLC | 5 | $100 |
| Merck | 7 | $96 |
| Jazz Pharmaceuticals Inc. | 5 | $79 |
| Eisai Inc. | 4 | $73 |
| Noven Therapeutics, LLC | 4 | $62 |
| Acadia Pharmaceuticals Inc | 3 | $58 |
| Almatica Pharma LLC | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 3 | $34 |
| Amgen | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,948 in reported general payments places this provider in the 85th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $33,830 |
| VraylarCariprazine Hcl | 11 | $15,654 |
| SpravatoEsketamine Hcl | 12 | $13,390 |
| QuviviqDaridorexant Hcl | 11 | $5,517 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 110 | $4,794 |
| Chlorpromazine Hcl | 14 | $4,263 |
| Lisdexamfetamine Dimesylate | 13 | $2,202 |
| FocalinDexmethylphenidate Hcl | 13 | $1,540 |
| Quetiapine Fumarate | 96 | $1,483 |
| Alprazolam | 239 | $1,400 |
| Bupropion XlBupropion Hcl | 49 | $1,303 |
| Oxcarbazepine | 25 | $1,192 |
| Duloxetine Hcl | 45 | $1,141 |
| Guanfacine Hcl ErGuanfacine Hcl | 13 | $1,135 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $1,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $959 | $33,83011 claims |
| AbbVieVraylar | $1,656 | $15,65411 claims |
| Johnson & JohnsonSpravato | $386 | $13,39012 claims |
| Almatica Pharma LLCSertraline Hcl | $56 | $258104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Leawood
- Kevin MaysLeawood$548K
- Sonni ElliottLeawood$22K
- Andrew SegravesLeawood$19K
- Michael EversonLeawood$19K
- Steven SegravesLeawood$13K
- Lolitta AznaurovaLeawood$11K
- Christopher van HornLeawood$10K
- Erick BrownLeawood$8K
- Wade HachinskyLeawood$7K
- Salma VelazquezLeawood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.